Research & Development
Novartis receives positive CHMP opinion for Itvisma in spinal muscular atrophy
24 April 2026 - Swiss pharmaceutical company Novartis AG (SIX:NOVN) (NYSE:NVS) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Servier completes Day One Biopharmaceuticals acquisition
24 April 2026 - French pharmaceutical company Servier announced on Thursday the successful completion of its tender offer to acquire all of the issued and outstanding shares of common stock of Day One...
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
24 April 2026 - Indian pharmaceutical company Cipla Limited (BSE:500087) (NSE:CIPLA-EQ) and its US subsidiary Cipla USA Inc announced on Thursday that the US Food and Drug Administration (FDA) has giv...
FDA expands Sanofi and Regeneron's Dupixent approval to younger children with chronic spontaneous urticaria
23 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) announced late Wednesday that the US Fo...
WuXi Biologics gains MFDS approval for three Wuxi manufacturing sites
...
OrganaBio and RxMP Therapeutics partner to advance RMP-402 haemostatic drug product
23 April 2026 - Blood and cell products and services company OrganaBio LLC and RxMP Therapeutics Inc, a late pre-clinical development stage therapeutics company developing novel therapies for the rapi...